< 生产厂家 价格 >

阿西美辛

阿西美辛用途

【用途一】
具有抗炎镇痛作用,用于类风湿性关节炎、骨关节炎等
【用途二】
非甾体消炎镇痛药,有明显抑制炎症的作用。适用于风湿性关节炎、类风湿性关节炎、肌纤维组织炎、坐骨神经痛等的治疗。
【用途三】
消炎镇痛药。乙酰消炎痛是消炎痛的前体药物,在体内经代谢变成消炎痛而发挥作用。由于本品的抗炎作用强,对胃肠道系统粘膜损害作用非常小,故与消炎痛相比,治疗范围更广。
点击显示

阿西美辛名称

[ CAS 号 ]:
53164-05-9

[ 中文名 ]:
阿西美辛

[ 英文名 ]:
acemetacin

[中文别名 ]:

[英文别名 ]:

阿西美辛生物活性

阿西美辛物理化学性质

[ 密度 ]:
1.4±0.1 g/cm3

[ 沸点 ]:
565.5±50.0 °C at 760 mmHg

[ 熔点 ]:
151.5°C

[ 分子式 ]:
C21H18ClNO6

[ 分子量 ]:
415.824

[ 闪点 ]:
295.8±30.1 °C

[ 精确质量 ]:
415.082275

[ PSA ]:
94.83000

[ LogP ]:
3.20

[ 外观性状 ]:
从石油醚得淡黄色细微结晶,熔点150-153℃。急性毒性LD50雄、雌小鼠,雄、雌大鼠(mg/kg):55.5,18.42,24.2,30.1口服;34.1,51.1,38.1,28.3静脉注射。

[ 蒸汽压 ]:
0.0±1.6 mmHg at 25°C

[ 折射率 ]:
1.611

[ 储存条件 ]:
-20°C Freezer

阿西美辛MSDS

阿西美辛毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NL3521400
CHEMICAL NAME :
1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester
CAS REGISTRY NUMBER :
53164-05-9
BEILSTEIN REFERENCE NO. :
0501672
LAST UPDATED :
199612
DATA ITEMS CITED :
24
MOLECULAR FORMULA :
C21-H18-Cl-N-O6
MOLECULAR WEIGHT :
415.85
WISWESSER LINE NOTATION :
T56 BNJ BVR& C1 D1VO1VQ GO1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
24200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
23 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
28400 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
28300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
19300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
18420 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
23300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
22800 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
34100 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
27600 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
64200 ug/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,657,1981
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
>600 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
300 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
194 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
192 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
280 mg/kg/35D-C
TOXIC EFFECTS :
Gastrointestinal - ulceration or bleeding from stomach Endocrine - other changes Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,665,1981 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
13500 ug/kg
SEX/DURATION :
female 17-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,777,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
56 mg/kg
SEX/DURATION :
female 16-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
44 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Newborn - behavioral
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,765,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
88 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - live birth index (measured after birth)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,765,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
108 mg/kg
SEX/DURATION :
female 17-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,777,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
351 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
点击显示

阿西美辛安全信息

[ 符号 ]:

GHS06

[ 信号词 ]:
Danger

[ 危害声明 ]:
H300 + H310 + H330

[ 警示性声明 ]:
Missing Phrase - N15.00950417-P260-P262-P280-P302 + P352 + P310-P304 + P340 + P310

[ 个人防护装备 ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T+:Verytoxic;

[ 风险声明 (欧洲) ]:
R26/27/28

[ 安全声明 (欧洲) ]:
S22-S25-S36/37/39-S45

[ 危险品运输编码 ]:
UN 2811

[ RTECS号 ]:
NL3521400

[ 包装等级 ]:
II

[ 危险类别 ]:
6.1(a)

[ 海关编码 ]:
2942000000

阿西美辛合成路线

阿西美辛上下游产品

阿西美辛制备

【方法一】
方法1:以在吲哚美辛的合成中得到的N-(4-甲氧基苯基)-4-氯苯甲酰肼为原料,和(3-乙酰基丙酰氧基)乙酸苄酯(其制备见方法3)环合,得到[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酰氧基]乙酸苄酯(I)。得到的苄酯(I)溶于冰醋酸中,在室温下在钯-炭催化剂上进行加氢,当氢吸收停止后,过滤去催化剂,滤液减压浓缩,残液加入石油醚中重结晶,得阿西美辛精品,熔点149.5~150.5℃,收率93%。
方法2:以吲哚美新为原料。
在搅拌下,将180g(0.503mo1)吲哚美新溶于900ml无水二甲基甲酰胺,加入35g(0.253mo1)磨细和干燥的碳酸钾,在50℃下搅拌45min。在15min中,滴入128g(0.56mo1)溴乙酸苄酯,在50℃下搅拌3h。过滤,滤液浓缩,剩余物溶于氯仿,用水洗至中性,无水硫酸钠干燥。浓缩,异丙醚-乙酸乙酯重结晶,得228g化合物(I),收率89.5%,熔点96℃。
60g(0.12mo1)化合物(I)溶于700ml乙酸乙酯,加入6g 5%钯-炭催化剂,在40℃下氢化1h,吸收约2.921L氢气(20℃)。过滤,浓缩,往剩余物加入石油醚(40~60℃),使结晶完全,并在冰箱中放置12h。过滤,先空气中干燥,后真空干燥,得46g阿西美辛,收率93%,熔点150~153℃。
方法3:以对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯为原料。
(3-乙酰基丙酰氧基)乙酸苄酯的制备。93.5g(0.68mo1)干燥碳酸钾悬浮于650ml无水二甲基甲酰胺,加热至40℃,在70min内滴入116.1g(1.0mo1)3-乙酰基丙酸。加毕,冷至30℃,加入229.1g(1.0mo1)2-溴乙酸苄酯。在50℃下反应4h。过滤除去无机盐,用甲苯提取。提取液浓缩,剩余物溶于400ml二氯甲烷,水洗至中性,无水硫酸钠干燥。浓缩,剩余物溶于。1000ml异丙醚,加入冷至-25℃的1500ml石油醚(40~60℃),于-15℃下放置1h。过滤,在22℃下真空干燥,得235g(3-乙酰基丙酰氧基)乙酸苄酯,收率89%,熔点31.5~32.5℃,沸点176~178℃/1.20kPa。
26.3g(0.19mo1)对甲氧基苯肼溶于125ml冰乙酸和450ml水,在搅拌下,滴入50g(0.19mo1)(3-乙酰基丙酰氧基)乙酸苄酯,再搅拌1h。用甲苯提取,提取液水洗至中性,干燥,浓缩,得75.5g棕色油状的化合物(Ⅱ),直接用于下列反应。
将化合物(Ⅱ)直接溶于125ml无水吡啶,加入500ml无水乙醚,再在0℃加入43.5g对氯苯甲酰氯在250ml无水乙醚的溶液,在氮气保护下回流2h,冷却,水洗至中性,干燥,浓缩,得95g化合物(Ⅲ)的粗品。无需提纯,直接用于下步反应。
将化合物(Ⅲ)直接溶于380ml乙酸,在80℃下加热5min。减压浓缩,剩余物溶于氯仿,用碳酸氢钠溶液洗,并水洗至中性。用氧化铝层析,氯仿洗脱。浓缩后用乙醚重结晶,得10.6g化合物(I)。从对甲氧基苯肼计,收率11%。化合物(I)再如方法2还原为阿西美辛。
方法4:对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯也可先环合,再对氯苯甲酰化。
45.7g(0.26mo1)对甲氧基苯肼盐酸盐和69.2g(0.26mo1)(3-乙酰基丙酰氧基)乙酸苄酯溶于260ml乙酸,先在28℃搅拌42h,再在50℃搅拌5h。蒸出150~180ml溶剂后,加入500ml冰水,用4×100ml甲苯提取。提取液合并,用碳酸氢钾溶液洗至无酸,无水硫酸钠干燥。过滤,浓缩,得92g粗品。经蒸馏,可得76g化合物(IV),收率80%,沸点165℃(≤100Pa)。
77.5g(0.44mo1)对氯苯甲酰氯溶于275ml专用石油(沸点180~220℃)中加热至沸,在20min中,滴加41g(0.1lmo1)化合物(Ⅳ)。加毕,在190-195℃加热2~3h,至无氯化氢放出。冷至40℃,加入200ml乙醚。在室温下结晶后,再放入冰箱过夜。过滤收集结晶,用异丙醚洗,再用乙酸乙酯和异丙醚重结晶,得43.3g化合物(I),收率78%。化合物(I)再如方法2还原为阿西美辛。
【方法二】
以消炎痛为原料,在乙醚-吡啶中与氯化亚砜反应生成消炎痛的酸性酰氯化物,然后在干燥吡啶中与乙醇酸反应得乙酰消炎痛。收率为54%。也可由消炎痛与氯代乙酸乙酯在DMF溶液中反应制得。
点击显示

阿西美辛海关

[ 海关编码 ]: 2933990090

[ 中文概述 ]:
2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

阿西美辛文献

A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis.

Phlebology 24(2) , 56-60, (2009)

The optimal treatment of superficial vein thrombosis (SVT) of the leg has not been determined yet. The aim of this study is to evaluate the efficacy of low-molecular-weight heparin (LMWH) as compared ...

A fast and reliable spectroscopic method for the determination of membrane--water partition coefficients of organic compounds.

Lipids 36(1) , 89-96, (2001)

Partition coefficients (Kp) between egg yolk phosphatidylcholine multilamellar vesicles and water were determined for two nonsteroidal anti-inflammatory drugs (indomethacin and acemetacin) using two i...

Multivariate optimization of separation conditions for simultaneous determination of acemetacin and chlorzoxazone in a pharmaceutical preparation by HPLC using response surface methodology.

J. AOAC Int. 96(4) , 723-9, (2013)

A new, fast, accurate, precise, and sensitive RP-HPLC method for the simultaneous determination of acemetacin and chlorzoxazone has been developed. Response surface methodology with a central composit...


更多文献

相关化工产品/化学物质:

相关药品:

推荐生产厂家/供应商:

公司名:上海吉至生化科技有限公司

区域:上海市奉贤区

价格:
¥168.0/25g

联系人:刘佳

产品详情:阿西美辛


公司名:上海源溪生物科技有限公司

区域:上海市浦东新区

价格:
¥需询单/1g

联系人:赖经理

产品详情:Acemetacin


公司名:上海脉铂医药科技有限公司

区域:上海市嘉定区

价格:
¥1039.0/5g ¥659.0/1g ¥489.0/1g ¥需询单/1g

联系人:李先生

产品详情:Acemetacin


公司名:上海创赛科技有限公司

区域:上海市嘉定区

价格:
¥72.0/5g ¥129.0/25g ¥1029.0/5g ¥656.6/1g

联系人:夏言

产品详情:[Perfemiker]阿西美辛,98%


公司名:上海阿拉丁生化科技股份有限公司

区域:上海市浦东新区

价格:
¥32.9/1g ¥67.9/5g ¥133.9/25g ¥需询单/1g

联系人:阿拉丁李高志

产品详情:阿西美辛


查看所有供应商请点击:

阿西美辛供应商


相关化合物

【阿西美辛】化源网提供阿西美辛CAS号53164-05-9,阿西美辛MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询阿西美辛上化源网,专业又轻松。>>电脑版:阿西美辛

标题:阿西美辛_MSDS_用途_密度_阿西美辛CAS号【53164-05-9】_化源网 地址:https://m.chemsrc.com/mip/cas/53164-05-9_164356.html